SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-24-000274
Filing Date
2024-03-08
Accepted
2024-03-08 16:34:44
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss3118746_sc13da.htm SC 13D/A 77210
2 JOINT FILING AGREEMENT ss3118746_ex9901.htm EX-99.1 5394
  Complete submission text file 0000947871-24-000274.txt   84204
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Subject) CIK: 0001661059 (see all company filings)

IRS No.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91004 | Film No.: 24734989
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)